Genmab | GEN - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.58B 354M 2026-03
argenx SE USD 355M 74.62M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Bayer EUR 3.7B 356M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Demant DKK 6.09B 135M 2025-12
Exelixis USD 139.6M 16.58M 2026-03
Fresenius Medical Care EUR 749M 36M 2026-03
Genmab DKK 208M 60M 2025-12
GlaxoSmithKline GBP 2.12B 558M 2026-03
GN Store Nord DKK 763M 688M 2026-03
GRIFOLS EUR 281M 5.7M 2026-03
Hikma Pharmaceutical USD 288M 149M 2025-12
Insmed USD 247.26M 34.78M 2026-03
Lakefront Biotherapeutics EUR 35.5M 8.91M 2026-03
Merck EUR 1.52B 80M 2026-03
Novartis USD 3.14B 296M 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.33B 419M 2026-03
UCB EUR 1.47B 193M 2025-12